Avidity Biosciences Inc
NASDAQ:RNA

Watchlist Manager
Avidity Biosciences Inc Logo
Avidity Biosciences Inc
NASDAQ:RNA
Watchlist
Price: 35.95 USD 4.02% Market Closed
Market Cap: 4.3B USD

Net Margin
Avidity Biosciences Inc

-4 136%
Current
-2 288%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-4 136%
=
Net Income
-369.2m
/
Revenue
8.9m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
Avidity Biosciences Inc
NASDAQ:RNA
4.3B USD
-4 136%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
337.7B USD
7%
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD
-2 848%
US
Amgen Inc
NASDAQ:AMGN
163.2B USD
17%
US
Gilead Sciences Inc
NASDAQ:GILD
142.2B USD
21%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.4B USD
-9%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
133.2B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.4B USD
32%
US
Seagen Inc
F:SGT
39.3B EUR
-33%

Avidity Biosciences Inc
Glance View

Market Cap
4.3B USD
Industry
Biotechnology

Avidity Biosciences Inc. is a biopharmaceutical company on the cutting edge of science devoted to treating severe diseases through breakthrough technology. Founded in 2012, Avidity's primary innovation lies in its pioneering platform known as the Antibody Oligonucleotide Conjugates (AOCs). This inventive approach merges the precision-targeting abilities of monoclonal antibodies with the potent gene-modulating capabilities of oligonucleotides. By effectively leveraging these two technologies, Avidity aims to address previously undruggable genetic conditions, providing new therapeutic avenues for diseases such as muscular dystrophies and other serious genetic disorders. The company channels its efforts into discovering, developing, and ultimately bringing these transformative therapies to market. The economic lifeline of Avidity Biosciences is deeply intertwined with its robust research and development pipeline, strategically focused partnerships, and potential revenue streams emanating from successful clinical trials. By innovating within the realm of RNA therapeutics, Avidity taps into collaborations with major pharmaceutical entities, further bolstering its financial standing. For instance, its collaborations often entail upfront technology access fees and potential milestone payments as drug candidates progress through clinical stages. Avidity's long-term financial model rests on the successful commercialization of its unique AOCs. Through these multifaceted operations, the company aims to generate sustainable revenue while making significant impacts in precision medicine, exemplifying a model that merges groundbreaking science with strategic industry alliances.

RNA Intrinsic Value
22.76 USD
Overvaluation 37%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-4 136%
=
Net Income
-369.2m
/
Revenue
8.9m
What is the Net Margin of Avidity Biosciences Inc?

Based on Avidity Biosciences Inc's most recent financial statements, the company has Net Margin of -4 136%.

Back to Top